Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims: Davalintide is a second‐generation amylinomimetic peptide possessing enhanced pharmacological properties over rat amylin to reduce food intake in preclinical models. The current experiments in rats describe additional glucoregulatory actions of davalintide consistent with amylin agonism, and explore the duration of action of these effects. Methods: Subcutaneous (SC) injection of davalintide slowed gastric emptying with equal potency to amylin (ED 50 's = 2.3 and 4.1 µg/kg). This effect was maintained for 8 h with davalintide, but not amylin. Intraperitoneal injection of davalintide also reduced food intake with a potency similar to amylin (ED 50 's = 5.0 and 11.3 µg/kg). Consistent with amylin agonism, davalintide (10 µg/kg, SC) suppressed the plasma glucagon response over 90 min following an intravenous arginine bolus in anaesthetized rats. The elimination t 1/2 of davalintide (200 µg/kg, SC) was 26 min, similar to the t 1/2 of amylin, suggesting that pharmacokinetic‐independent mechanisms contribute to davalintide's enhanced duration of action. Binding kinetic studies using 125 I davalintide revealed no appreciable dissociation from the amylin nucleus accumbens receptor after 7 h while 125 I rat amylin did dissociate from this receptor ( K off = 0.013/min). Sustained SC infusion of davalintide (275 µg/kg/day) or amylin (300) decreased plasma glucose after an oral glucose challenge at 2 weeks (by 27 and 31%) and suppressed gastric emptying at 3 weeks (by 29 and 47%), demonstrating durable glucoregulatory actions of both peptides. Conclusions: These data show glucoregulatory properties of davalintide consistent with amylin agonism and suggest that slowed receptor dissociation plays a role in davalintide's prolonged pharmacodynamic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837 · cited 1×
“This leads to excess hepatic glucose production and contributes to postprandial hyperglycaemia [34,35].”
BackgroundRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Self-citationEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205 · cited 1×
“Pramlintide reduced 24-h food intake [22] and meal size after a single meal [23], while sustained decreases in body weight were observed with and without lifestyle intervention in obese subjects [24,25].”
BackgroundAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“Pramlintide reduced 24-h food intake [22] and meal size after a single meal [23], while sustained decreases in body weight were observed with and without lifestyle intervention in obese subjects [24,25].”
BackgroundSmith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C. (2008) · Diabetes Care · doi:10.2337/dc08-0029 · Cited by 172 · cited 1×
“Pramlintide reduced 24-h food intake [22] and meal size after a single meal [23], while sustained decreases in body weight were observed with and without lifestyle intervention in obese subjects [24,25].”
BackgroundInfusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
Kong, M.-F., King, P., Macdonald, I. A., Stubbs, T. A., Perkins, A. C., Blackshaw, P. E., Moyses, C., & Tattersall, R. B. (1997) · Diabetologia · doi:10.1007/s001250050646 · Cited by 131
Fineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Metabolism · doi:10.1053/meta.2002.32022 · Cited by 129
Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112 · cited 1×
“Pramlintide delayed gastric emptying in patients with type 1 [4,5] and type 2 diabetes [6], being equally effective in both populations [6].”
BackgroundThe effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM
Kong, M.-F., Stubbs, T. A., King, P., Macdonald, I. A., Lambourne, J. E., Blackshaw, P. E., Perkins, A. C., & Tattersall, R. B. (1998) · Diabetologia · doi:10.1007/s001250050949 · Cited by 106
Cited by
Amylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Self-citationFuture Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Bower, R. L., & Hay, D. L. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13496 · Cited by 104
Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias
Andreassen, K. V., Hjuler, S. T., Furness, S. G., Sexton, P. M., Christopoulos, A., Nosjean, O., Karsdal, M. A., & Henriksen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092042 · Cited by 89
Boccia, L., Gamakharia, S., Coester, B., Whiting, L., Lutz, T. A., & Le Foll, C. (2020) · Peptides · doi:10.1016/j.peptides.2020.170366 · Cited by 70
“It is thought that early satiation signals like amylin impede food consumption by moderating reward system activity, reducing its value [91,116,117].”
Metadata
- Authors
- Mack, C. M., Smith, P. A., Athanacio, J. R., Xu, K., Wilson, J. K., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-10-27
- Volume
- 13
- Issue
- 12
- Pages
- 1105-1113
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2041263309
- Cited by
- 49
- References
- 9
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01465.x
- The paper
- Mack, C. M., Smith, P. A., Athanacio, J. R., Xu, K., Wilson, J. K., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011). Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01465.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.